<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453581</url>
  </required_header>
  <id_info>
    <org_study_id>QP12C10</org_study_id>
    <nct_id>NCT02453581</nct_id>
  </id_info>
  <brief_title>Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers</brief_title>
  <official_title>An Experimental Study To Characterize the Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queensland Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single centre, open, controlled study using Blood Stage Plasmodium falciparum challenge
      inoculum (BSPC) as a model to assess the effectiveness of three dose levels of the
      experimental anti-malarial product, OZ439.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single center study using blood stage Plasmodium falciparum challenge inoculum to
      characterize the effectiveness of OZ439 against early blood stage Plasmodium Falciparum
      infection.

      The study was conducted in three cohorts (n=8) using different doses of OZ439. Dose
      escalation took place after review of the observed OZ439 safety and pharmacodynamic outcome
      for the previous cohort by the Safety Review Team.

      Single doses of 100 mg, 200 mg and 500 mg were administered orally to participants in Cohort
      1, Cohort 2 and Cohort 3 respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual Parasite Reduction Ratio (PRR)</measure>
    <time_frame>48 hours</time_frame>
    <description>PRR estimates the efficacy of an anti-malarial treatment and is the ratio of the parasite density between admission and 48 hours post-treatment.
Individual subject PRR and corresponding 95% CI were calculated using the slope and corresponding standard error of mean (SE) of the optimal regression model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>500mg Cohort Mean Parasite Reduction Ratio (PRR)</measure>
    <time_frame>48 hours</time_frame>
    <description>OZ439 500mg individual subject PRR and corresponding 95% CI were used to calculate the OZ439 500mg cohort specific PRR and the corresponding 95% CI: the weighted average slope estimate and corresponding SE were calculated by the inverse-variance method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OZ439 Cmax</measure>
    <time_frame>Pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
    <description>OZ439 Maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OZ439 AUC(0-144)</measure>
    <time_frame>Pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
    <description>OZ439 Area under the curve to 144 hours</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>OZ439 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 100mg Powder for Oral Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 200mg Powder for Oral Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 500mg Powder for Oral Suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439</intervention_name>
    <description>OZ439 Powder for Oral Suspension</description>
    <arm_group_label>OZ439 100mg</arm_group_label>
    <arm_group_label>OZ439 200mg</arm_group_label>
    <arm_group_label>OZ439 500mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers will be adults (males or non pregnant females), aged between 18 and 45
             years who do not live alone (from Day 1 until at least the end of the antimalarial
             drug treatment).

          -  Volunteers must have a BMI within the range 18-30.

          -  Volunteers must understand the procedures involved and agree to participate in the
             study by giving fully informed, written consent.

          -  Be contactable and available for the duration of the trial (maximum of 4 weeks).

          -  Volunteers must be non-smokers and in good health, as assessed during pre-study
             medical examination and by review of screening results.

          -  Female participants of childbearing potential, should be surgically sterile or using
             an insertable, injectable, transdermal, or combination oral contraceptive approved by
             the US FDA or Therapeutic Goods Administration (TGA) combined with a barrier
             contraceptive through completion of the study and have negative results on a serum or
             urine pregnancy test done before administration of study medication.

          -  Good peripheral venous access.

        Exclusion Criteria:

          -  History of malaria.

          -  Travelled to or lived (2 weeks or more) in a malaria-endemic country during the past
             12 months or planned travel to a malaria-endemic country during the course of the
             study.

          -  Has evidence of increased cardiovascular disease risk (defined as greater than 10%, 5
             year risk)

          -  History of splenectomy.

          -  History of a severe allergic reaction, anaphylaxis or convulsions following any
             vaccination or infusion.

          -  Presence of current or suspected serious chronic diseases such as cardiac or
             autoimmune disease (HIV or other immunodeficiencies), insulin dependent diabetes,
             progressive neurological disease, severe malnutrition, acute or progressive hepatic
             disease, acute or progressive renal disease, psoriasis, rheumatoid arthritis, asthma,
             epilepsy or obsessive compulsive disorder, skin carcinoma excluding non-spreadable
             skin cancers such as basal cell and squamous cell carcinoma.

          -  Known inherited genetic anomaly (known as cytogenetic disorders) e.g., Down's syndrome

          -  Volunteers unwilling to defer blood donations to the Australian Red Cross Blood
             Service (ARCBS) for 6 months.

          -  The volunteer has a diagnosis of schizophrenia, severe depression, bi-polar disease,
             or other severe (disabling) chronic psychiatric diagnosis. Participants who are
             receiving a single antidepressant drug and are stable for at least 3 months prior to
             enrollment without decompensating may be allowed to enroll in the study at the
             investigator's discretion. 10) Presence of acute infectious disease or fever (e.g.,
             sub-lingual temperature 38.5 degrees C) within the five days prior to study product
             administration.

          -  Evidence of acute illness within the four weeks before trial prior to screening.

          -  Significant intercurrent disease of any type, in particular liver, renal, cardiac,
             pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical
             examination, and/or laboratory studies including urinalysis.

          -  Have ever received a blood transfusion.

          -  Evidence of any condition that, in the opinion of the clinical investigator, might
             interfere with the evaluation of the study objectives or pose excessive risks to
             participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCarthy, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Q-Pharm Pty Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>QLD 4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <results_first_submitted>June 18, 2015</results_first_submitted>
  <results_first_submitted_qc>June 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2015</results_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OZ439 100mg</title>
          <description>OZ439 100mg Powder for Oral Suspension</description>
        </group>
        <group group_id="P2">
          <title>OZ439 200mg</title>
          <description>OZ439 200mg Powder for Oral Suspension</description>
        </group>
        <group group_id="P3">
          <title>OZ439 500mg</title>
          <description>OZ439 500mg Powder for Oral Suspension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects enrolled in the study received a single dose of OZ439.</population>
      <group_list>
        <group group_id="B1">
          <title>Randomised Participants</title>
          <description>Twenty-four male and female subjects were enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - 30 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 - 40 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 - 45 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Individual Parasite Reduction Ratio (PRR)</title>
        <description>PRR estimates the efficacy of an anti-malarial treatment and is the ratio of the parasite density between admission and 48 hours post-treatment.
Individual subject PRR and corresponding 95% CI were calculated using the slope and corresponding standard error of mean (SE) of the optimal regression model.</description>
        <time_frame>48 hours</time_frame>
        <population>As the doses of 100 mg and 200 mg of OZ439 in Cohorts 1 and 2 were inadequate to eliminate the parasites and regrowth occurred, PRR calculations were only undertaken for subjects receiving 500mg of OZ439 in Cohort 3.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 500mg - R017</title>
            <description>Cohort 3 - OZ439 500mg - Subject R017</description>
          </group>
          <group group_id="O2">
            <title>OZ439 500mg - R018</title>
            <description>Cohort 3 - OZ439 500mg - Subject R018</description>
          </group>
          <group group_id="O3">
            <title>OZ439 500mg - R019</title>
            <description>Cohort 3 - OZ439 500mg - Subject R019</description>
          </group>
          <group group_id="O4">
            <title>OZ439 500mg - R020</title>
            <description>Cohort 3 - OZ439 500mg - Subject R020</description>
          </group>
          <group group_id="O5">
            <title>OZ439 500mg - R021</title>
            <description>Cohort 3 - OZ439 500mg - Subject R021</description>
          </group>
          <group group_id="O6">
            <title>OZ439 500mg - R022</title>
            <description>Cohort 3 - OZ439 500mg - Subject R022</description>
          </group>
          <group group_id="O7">
            <title>OZ439 500mg - R023</title>
            <description>Cohort 3 - OZ439 500mg - Subject R023</description>
          </group>
          <group group_id="O8">
            <title>OZ439 500mg - R024</title>
            <description>Cohort 3 - OZ439 500mg - Subject R024</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Parasite Reduction Ratio (PRR)</title>
          <description>PRR estimates the efficacy of an anti-malarial treatment and is the ratio of the parasite density between admission and 48 hours post-treatment.
Individual subject PRR and corresponding 95% CI were calculated using the slope and corresponding standard error of mean (SE) of the optimal regression model.</description>
          <population>As the doses of 100 mg and 200 mg of OZ439 in Cohorts 1 and 2 were inadequate to eliminate the parasites and regrowth occurred, PRR calculations were only undertaken for subjects receiving 500mg of OZ439 in Cohort 3.</population>
          <units>none (ratio)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1132" lower_limit="357" upper_limit="3587"/>
                    <measurement group_id="O2" value="217646" lower_limit="21471" upper_limit="2206216"/>
                    <measurement group_id="O3" value="314040" lower_limit="42823" upper_limit="2302975"/>
                    <measurement group_id="O4" value="8021" lower_limit="147" upper_limit="438967"/>
                    <measurement group_id="O5" value="8227" lower_limit="2665" upper_limit="25403"/>
                    <measurement group_id="O6" value="13557" lower_limit="3113" upper_limit="59037"/>
                    <measurement group_id="O7" value="13560" lower_limit="3320" upper_limit="55381"/>
                    <measurement group_id="O8" value="21924" lower_limit="1486" upper_limit="323346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 Cmax</title>
        <description>OZ439 Maximum concentration (Cmax)</description>
        <time_frame>Pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
        <population>All 24 subjects randomized and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg</title>
            <description>OZ439 100mg Powder for Oral Suspension</description>
          </group>
          <group group_id="O2">
            <title>OZ439 200mg</title>
            <description>OZ439 200mg Powder for Oral Suspension</description>
          </group>
          <group group_id="O3">
            <title>OZ439 500mg</title>
            <description>OZ439 500mg Powder for Oral Suspension</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Cmax</title>
          <description>OZ439 Maximum concentration (Cmax)</description>
          <population>All 24 subjects randomized and completed the study.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" spread="20"/>
                    <measurement group_id="O2" value="448" spread="33"/>
                    <measurement group_id="O3" value="1263" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OZ439 AUC(0-144)</title>
        <description>OZ439 Area under the curve to 144 hours</description>
        <time_frame>Pre-dose, and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose</time_frame>
        <population>All 24 subjects randomized and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg</title>
            <description>OZ439 100mg Powder for Oral Suspension</description>
          </group>
          <group group_id="O2">
            <title>OZ439 200mg</title>
            <description>OZ439 200mg Powder for Oral Suspension</description>
          </group>
          <group group_id="O3">
            <title>OZ439 500mg</title>
            <description>OZ439 500mg Powder for Oral Suspension</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC(0-144)</title>
          <description>OZ439 Area under the curve to 144 hours</description>
          <population>All 24 subjects randomized and completed the study.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1056" spread="23"/>
                    <measurement group_id="O2" value="3182" spread="21"/>
                    <measurement group_id="O3" value="10755" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>500mg Cohort Mean Parasite Reduction Ratio (PRR)</title>
        <description>OZ439 500mg individual subject PRR and corresponding 95% CI were used to calculate the OZ439 500mg cohort specific PRR and the corresponding 95% CI: the weighted average slope estimate and corresponding SE were calculated by the inverse-variance method.</description>
        <time_frame>48 hours</time_frame>
        <population>As the doses of 100 mg and 200 mg of OZ439 in Cohorts 1 and 2 were inadequate to eliminate the parasites and regrowth occurred, PRR calculations were only undertaken for subjects receiving 500mg of OZ439 in Cohort 3. With a p value of 0.0046, Subject S036 was excluded from this calculation</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 500mg Arm</title>
            <description>Cohort 3 - OZ439 500mg</description>
          </group>
        </group_list>
        <measure>
          <title>500mg Cohort Mean Parasite Reduction Ratio (PRR)</title>
          <description>OZ439 500mg individual subject PRR and corresponding 95% CI were used to calculate the OZ439 500mg cohort specific PRR and the corresponding 95% CI: the weighted average slope estimate and corresponding SE were calculated by the inverse-variance method.</description>
          <population>As the doses of 100 mg and 200 mg of OZ439 in Cohorts 1 and 2 were inadequate to eliminate the parasites and regrowth occurred, PRR calculations were only undertaken for subjects receiving 500mg of OZ439 in Cohort 3. With a p value of 0.0046, Subject S036 was excluded from this calculation</population>
          <units>none (ratio)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10176" lower_limit="5757" upper_limit="17986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>144 hours</time_frame>
      <desc>24 subjects who participated in the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>OZ439 100mg</title>
          <description>OZ439 100mg Powder for Oral Suspension</description>
        </group>
        <group group_id="E2">
          <title>OZ439 200mg</title>
          <description>OZ439 200mg Powder for Oral Suspension</description>
        </group>
        <group group_id="E3">
          <title>OZ439 500mg</title>
          <description>OZ439 500mg Powder for Oral Suspension</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rapid Regular Heart Rate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty Focusing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication and reporting of results and outcomes of this trial will be accurate and honest, undertaken with integrity and transparency and in accordance with QIMRâ€™s Policy on Criteria for Authorship. Publication of results will be subjected to fair peer-review. Data will not be released publicly until the manuscript is accepted for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr James McCarthy</name_or_title>
      <organization>Qeensland Institute of Medical Research</organization>
      <phone>+61 7 3845 3796</phone>
      <email>James.McCarthy@qimr.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

